Evidence map›Paper›PMID 28402261›Full record

ArticleOncotarget2017

Association of CKIP-1 P21A polymorphism with risk of chronic heart failure in a Chinese population.

Mu-Peng Li, Yan-Jiao Zhang, Xiao-Lei Hu, Ji-Peng Zhou, Yong-Long Yang, Li-Ming Peng, Hong Qi, Tian-Lun Yang, Xiao-Ping Chen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Upregulation ofCell & bioscience · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Mu-Peng LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China.
Yan-Jiao ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China.
Xiao-Lei HuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China.
Ji-Peng ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China.
Yong-Long YangHaikou People's Hospital and Affiliated Haikou Hospital of Xiangya Medical School, Central South University, Haikou 570311, Hainan, P. R. China.
Li-Ming PengDepartment of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China.
Hong QiDepartment of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China.
Tian-Lun YangDepartment of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China.
Xiao-Ping ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China.
Xiangya Hospital Central South University · CNCentral South University · CNHaikou City People's Hospital · CNPharmacoGenetics (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathological cardiac hypertrophy is an independent risk factor for chronic heart failure. Casein kinase-2 interacting protein-1 (CKIP-1) can inhibit pathological cardiac hypertrophy. Therefore, we investigated whether CKIP-1 nonsynonymous polymorphism rs2306235 (Pro21Ala) contributes to risk and prognosis of chronic heart failure in a Chinese population.A total of 923 adult patients with chronic heart failure and 1020 age- and gender-matched healthy controls were recruited. CKIP-1 rs2306235 polymorphism was genotyped using PCR-restriction fragment length polymorphism. Additional follow-up data for 140 chronic heart failure patients was evaluated. The rs2306235 G allele was associated with an increased risk of chronic heart failure (OR = 1.38, 95% CI = 1.09-1.75, p = 0.007), especially in patients with hypertension (OR = 1.45, 95% CI = 1.09-1.75, p = 0.006) and coronary heart disease (OR = 1.41, 95% CI = 1.09-1.83, p = 0.010) after adjustment for multiple cardiovascular risk factors. However, rs2306235 polymorphism was not associated with cardiovascular mortality in chronic heart failure (p = 0.875). CKIP-1 rs2306235 polymorphism may be a risk factor for chronic heart failure in a Chinese Han population.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAdultAgedAged, 80 and overAllelesAmino Acid SubstitutionAsian PeopleCase-Control StudiesChinaChronic DiseaseCodonFemaleGenotypeHeart FailureHumansCodonIntracellular Signaling Peptides and ProteinsPLEKHO1 protein, humancardiac hypertrophychronic heart failureCKIP-1polymorphismprognosis

Identifiers

PMID28402261
PMCPMC5482675
OpenAlexW2598493994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.